Related Experiment Video

Updated: Sep 27, 2026

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
10:43

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein

Published on: December 3, 2010

The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells

Vito Spataro1, Katia Simmen, Claudio A Realini

  • 1Oncology Institute of Southern Switzerland, Ospedale La Carita, 6600 Locarno, TI, Switzerland.

Anticancer Research
|January 30, 2003
PubMed
Abstract

Insights

Overexpressing the proteasome subunit Rpn11 in mammalian cells increases resistance to chemotherapy drugs like vinblastine and cisplatin. This Rpn11 overexpression also slows cell proliferation, potentially aiding tumor cell survival.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Identifying multidrug resistance (MDR) factors is critical for effective cancer chemotherapy.
  • Proteasome subunit dysfunction is implicated in cancer development and drug resistance.

Purpose of the Study:

  • To investigate the role of the proteasome subunit Rpn11 in multidrug resistance.
  • To analyze the impact of Rpn11 overexpression on cancer cell response to cytotoxic drugs.

Main Methods:

  • Analyzed Rpn11 expression levels in various cancer cell lines.
  • Utilized clonogenic cytotoxicity assays to assess drug resistance in cells overexpressing Rpn11.

Main Results:

  • Rpn11 expression varies significantly across different cancer cell types.
  • Stable Rpn11 overexpression conferred moderate resistance to vinblastine, cisplatin, and doxorubicin.
  • Cells overexpressing Rpn11 exhibited a reduced proliferation rate compared to control cells.

Conclusions:

  • Rpn11 overexpression influences mammalian cell proliferation and drug response.
  • These effects may contribute to tumor cell evasion of chemotherapy.
  • Rpn11 could serve as a potential biomarker for multidrug-resistant cancer cells.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells12:25

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells

Published on: July 21, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...